REBIRTH Trial: Evaluating Bromocriptine Therapy for Peripartum Cardiomyopathy

Maternal mortality in the United States is at its highest level since 1965. A particular area of crisis is within peripartum cardiomyopathy (PPCM), which is a major cause of pregnancy-related deaths. In this presentation, Dr. Deborah Crabbe, Cardiologist at Temple University Hospital and Professor of Medicine at Lewis Katz School of Medicine at Temple University, outlines the REBIRTH Trial, an NIH/NHLBI-funded multi-center, randomized trial to evaluate the use of bromocriptine to improve LVEF in women recently diagnosed with PPCM.

REBIRTH is a trial that will randomize 200 women at 60 centers across North America to determine if bromocriptine therapy improves myocardial recovery for women with PPCM.

Temple University Hospital is participating in this study. To refer a patient to Temple, please call 215-707-3898.

Click here to watch Dr. Crabbe's entire presentation, which includes a 20-year perspective about past studies of heart failure in women.

Refer a patient for the REBIRTH Trial

Created by

Temple Health


Deborah Crabbe, MD, FACC, FAHA

Deborah Crabbe, MD, FACC, FAHA

Professor, Medicine
Lewis Katz School of Medicine
Temple University

View full profile